This company has been acquired
Prometheus Biosciences Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Prometheus Biosciences's earnings have been declining at an average annual rate of -48.4%, while the Biotechs industry saw earnings growing at 32.7% annually. Revenues have been declining at an average rate of 36.5% per year.
Información clave
-48.4%
Tasa de crecimiento de los beneficios
43.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | -36.5% |
| Rentabilidad financiera | -21.6% |
| Margen neto | -3,768.8% |
| Última actualización de beneficios | 31 Mar 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M
Aug 11We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
Dec 08Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Prometheus Biosciences: Precision Medicine For IBD
Sep 22Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Prometheus Biosciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 23 | 4 | -151 | 45 | 0 |
| 31 Dec 22 | 7 | -142 | 40 | 0 |
| 30 Sep 22 | 7 | -133 | 29 | 0 |
| 30 Jun 22 | 7 | -123 | 29 | 0 |
| 31 Mar 22 | 6 | -108 | 31 | 0 |
| 31 Dec 21 | 3 | -90 | 29 | 0 |
| 30 Sep 21 | 3 | -69 | 25 | 0 |
| 30 Jun 21 | 2 | -50 | 18 | 0 |
| 31 Mar 21 | 2 | -38 | 14 | 0 |
| 31 Dec 20 | 1 | -31 | 11 | 0 |
| 31 Dec 19 | 1 | -17 | 6 | 0 |
Ingresos de calidad: RXDX is currently unprofitable.
Margen de beneficios creciente: RXDX is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: RXDX is unprofitable, and losses have increased over the past 5 years at a rate of 48.4% per year.
Acelerando crecimiento: Unable to compare RXDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: RXDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
Rentabilidad financiera
Alta ROE: RXDX has a negative Return on Equity (-21.58%), as it is currently unprofitable.